Element Capital Management
MTNB icon

Element Capital Management’s Matinas BioPharma MTNB Stock Holding History

Element Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-335
Closed -$231K – 801
2018
Q3 		$231K Sell
335
-190
-36% -$61.2K ﹤0.01% 704
2018
Q2 		$171K Buy
+525
New +$227K ﹤0.01% 753

Other funds holding MTNB

Boxer Capital
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Raymond James Financial Services Advisors
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Element Capital Management's MTNB Position: Q4 2018 in Review

Element Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2018, closing a stake of 335 shares — an estimated $231K sold.

Element Capital Management first reported a position in MTNB in Q2 2018 and held it in 2 quarters. The position peaked at $231K in Q3 2018. 34 funds tracked by Wall St. Rank hold MTNB as of Q4 2018.

  • Element Capital Management reported no remaining Matinas BioPharma position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 335 Matinas BioPharma shares in Q4 2018, an estimated $231K.
  • Element Capital Management first reported a position in Matinas BioPharma in Q2 2018 and held it in 2 quarters.
  • Element Capital Management's Matinas BioPharma position peaked at $231K in Q3 2018.
  • 34 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.